

# Hemodynamische en metabole complicaties van cardiorenale schade

**Prof. dr. Carlo Gaillard**

Internist-nefroloog, UMC Utrecht



# Outline

---

Cardiorenale schade. Epidemiologie en classificatie.

Co-occurrence of cardiorenal pathology, putative pathophysiological mechanisms


Conclusie

# Evolving definitions of cardiorenal syndrome


---

- The frequent presentation of combined cardiac and renal dysfunction *2004*
- The presence or development of renal dysfunction in patients with heart failure *2004*
- Severe cardiorenal syndrome is a pathophysiological condition in which combined cardiac and renal dysfunction amplifies progression of failure of the individual organs *2006*
- Cardiorenal syndrome is a pathophysiological disorder in which acute or chronic dysfunction of one organ may induce acute or chronic dysfunction in the other *2008*
- Each dysfunctional organ has the ability to initiate and perpetuate disease in the other organ through common hemodynamic, neurohormonal, and immunological and/or biochemical feedback pathways *2010*






# VALIANT: Renal disease in heart failure




# Cardiovascular disease and heart failure in CKD




# Classification of cardiorenal interaction

Syndromes	Acute cardio-renal (type 1)	Chronic cardio-renal (type 2)	Acute reno-cardiac (type 3)	Chronic reno-cardiac (type 4)	Secondary CRS (type 5)
Organ failure sequence					
Definition	Acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction	Chronic abnormalities in heart function (CHF-CHD) leading to kidney injury or dysfunction	Acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction	Chronic kidney disease (CKD) leading to heart injury, disease and/or dysfunction	Systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney

# DM, HF en CKD








# CKD, heart failure, and type 2 diabetes are interrelated, leading to a vicious circle of cardiac, renal and metabolic risk



**Diabetes**



2017 Global Prevalence<sup>1</sup>  
~476M



**CKD**



2017 Global Prevalence<sup>1</sup>  
~698M



**Heart Failure**



2017 Global Prevalence<sup>1</sup>  
~64M



CKD, chronic kidney disease; HF, heart failure; T2D, type 2 diabetes.

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. *Lancet*. 2018;392:1789-1858; 2. Parving HH et al. *Kidney Int*. 2006;69:2057-2063; 3. Birkeland KI et al. *Diabetes Obes Metab*. 2020;22:1607-1618; 4. Ronco C et al. *J Am Coll Cardiol*. 2008;52:1527-1539.


# Co-occurrence of cardiorenal pathology: putative pathophysiological interaction

Hemodynamics


Non hemodynamic “connectors”

Others


# Hemodynamics



B




# The renal tamponade hypothesis



normal state

decompensated state




normal state



decompensated state

- ① Nephron
- ② Renal venules
- ③ Renal arterioles

1. Increased intracapsular pressures; the rigidity of the capsule prevents expansion of the renal interstitium leading to high pressures with the renal interstitium, diminishing function of the several structures.



2. Increased perirenal pressure; increases in perirenal adipose tissue compress renal vasculature, exacerbating intrarenal congestion.



3. Increased peritoneal pressure; the weight of the peritoneal space, from either fat or fluid, compresses the renal vasculature, exacerbating renal congestion.


# Non-hemodynamic connectors

Renin Angiotensin Aldosterone System


Sympathetic Nervous System

Inflammation

Reactive Oxygen Species



# Pathophysiology of neurohumoral and inflammatory pathways involved in cardiorenal syndrome




# What identifies renal-disease-induced cardiovascular disease?

---


Accelerated atherosclerosis: a different, more rapid and extensive atherosclerotic process

Uremic cardiomyopathy/HFpEF

Underlying metabolic disorder



**Atherosclerosis**



**Mönckeberg's  
arteriosclerosis**




# Fibroblast growth factor 23: course in CKD


Fibroblast growth factor 23 (FGF23) is osteocyte-derived hormone which is an essential regulator of phosphate metabolism



FGF23 has been shown to be associated with an increased risk of mortality in RTR, and in many other patient populations

Calcium phosphate metabolism, LVH, Sodium regulation, Infection, Red cell production




# Red cell and iron






# Proposed renal protective pathways with SGLT2 inhibitors



# Kidney outcome trials with SGLT2 inhibitors address the spectrum of CKD



E=EMPAREG-Outcome; C=CANVAS; D=DECLARE TIMI-58

CKD, chronic kidney disease; DKD, diabetic kidney disease, eGFR, glomerular filtration rate; GFR, glomerular filtration rate  
Heerspink HJL, et.al. *Nephrol Dial Transplant* 2020;35:274–282

# Summary

---

The cardiorenal syndrome refers to a complex interaction between heart and kidney causing reciprocal damage through hemodynamic, neurohumoral and metabolic mechanisms including

- disturbed calcium/phosphate metabolism
- anemia and increased red cell turn over
- iron deficiency
- inflammation
- ?

# Summary

---

Mechanisms responsible for true reciprocal augmentation of damage are of utmost importance, warrant further studies and may allow development of new treatment approaches